Stereotactic Radiofrequency Ablation (SRFA) of intrahepatic cholangiocellular carcinomas: A minimal invasive alternative to liver resection

被引：4

作者：

Bale R. ^{[1
]}

Schullian P. ^{[1
]}

Haidu M. ^{[1
]}

Widmann G. ^{[1
]}

机构：

[1] SIP Univ.-Klinik für Radiodiagnostik, Universitätsklinik Innsbruck, Medizinische Universität Innsbruck, Innsbruck

来源：

Wiener Medizinische Wochenschrift | 2013年 / 163卷 / 5-6期

关键词：

Interventional radiology; Liver tumor; Locoablative therapy; Minimal invasive; Stereotactic Radiofrequency Ablation (SRFA);

D O I：

10.1007/s10354-013-0182-8

中图分类号：

学科分类号：

摘要：

Up to now resection and liver transplantation are concerned as the only curative treatment options for intrahepatic cholangiocellular carcinomas (ICCs). For patients with inoperable ICCs systemic chemotherapy and various locoregional therapies including transarterial (chemo)embolization (TACE), selective internal radiation therapy (SIRT), radiofrequency ablation (RFA) and microwave ablation (MWA) are applied. Stereotactic RFA (SRFA) allows for precise 3D planning and positioning of multiple RF electrodes. Due to overlapping necroses tumors > 5 cm can be completely ablated in one session. 17 inoperable consecutive patients with 52 ICCs were treated with stereotactic RFA (SRFA). A median overall survival of 60 months was achieved. The two largest tumors with diameters > 10 cm were completely ablated. These SRFA data of irresectable ICCs are superior to the published data on resection. SRFA is a minimal invasive alternative treatment to resection and may be considered as the first-line local treatment of patients with ICCs in selected patients.

引用

页码：128 / 131

页数：3

共 22 条

[1]

Deoliveira M.L., Cunningham S.C., Cameron J.L., Et al., Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution, Ann Surg, 245, pp. 755-762, (2007)

[2]

Aljiffry M., Abdulelah A., Walsh M., Et al., Evidence-based approach to cholangiocarcinoma: A systematic review of the current literature, J Am Coll Surg, 208, pp. 134-147, (2009)

[3]

Anderson C.D., Pinson C.W., Berlin J., Et al., Diagnosis and treatment of cholangiocarcinoma, Oncologist, 9, pp. 43-57, (2004)

[4]

De Groen P.C., Gores G.J., Larusso N.F., Et al., Biliary tract cancers, N Engl J Med, 341, pp. 1368-1378, (1999)

[5]

Kim J.H., Yoon H.K., Sung K.B., Et al., Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahe- patic cholangiocarcinoma: Clinical efficacy and factors influenc- ing outcomes, Cancer, 113, pp. 1614-1622, (2008)

[6]

Park S.Y., Kim J.H., Yoon H.J., Et al., Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahe- patic cholangiocarcinoma, Clin Radiol, 2011, 66, pp. 322-328

[7]

Kiefer M.V., Albert M., McNally M., Et al., Chemoembolization of intrahepa- tic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: A 2-center study, Cancer, 2011, 117, pp. 1498-1505

[8]

Herber S., Otto G., Schneider J., Et al., Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma, Cardiovasc Intervent Radiol, 30, pp. 1156-1165, (2007)

[9]

Vogl T.J., Nnn N., Nea N., Et al., Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success, Int J Cancer, 131, 3, pp. 733-740, (2012)

[10]

Aliberti C., Benea G., Tilli M., Et al., Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: Preliminary results, Cardiovasc Intervent Radiol, 31, pp. 883-888, (2008)

← 1 2 3 →